Stoke Therapeutics, Inc.
NASDAQ: STOK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ian F. Smith
- Employees
- 128
- Headquarters
- Bedford, United States
- IPO year
- 2019
- Market cap
- $1.9B
- Website
- https://www.stoketherapeutics.com
Loading STOK…
Loading profile data…Frequently asked questions about STOK
What does Stoke Therapeutics, Inc. (STOK) do?
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Ge...
Where does STOK trade?
Stoke Therapeutics, Inc. (STOK) trades on the NASDAQ Global Select.
What sector is STOK in?
Stoke Therapeutics, Inc. (STOK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Stoke Therapeutics, Inc.?
Ian F. Smith is the chief executive officer of Stoke Therapeutics, Inc. (STOK).
Where is Stoke Therapeutics, Inc. headquartered?
Stoke Therapeutics, Inc. is headquartered in United States.
Does STOK pay a dividend?
Stoke Therapeutics, Inc. (STOK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did STOK go public?
Stoke Therapeutics, Inc. (STOK) completed its initial public offering in 2019.